Abstract P5-18-24: Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates

Background: Trastuzumab emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate composed of the humanized monoclonal antibody trastuzumab, the potent cytotoxic agent DM1 (a microtubule inhibitor), and a stable thioether linker. To estimate typical pharmacokinetic (PK) parameter values and interpatient variability, a population PK model for T-DM1 was previously developed from 1 phase 1 (0.3 to 4.8 mg/kg in qw or q3w regimens) and 2 phase 2 (3.6 mg/kg q3w) trials (Gupta, J Clin Pharmacol 2012). The model reported here has been updated with additional data from 2 randomized trials (phase 2 TDM4450g and phase 3 EMILIA, 3.6 mg/kg q3w). Another phase 2 trial (TDM4688g) was used for external validation of the model. The effect of demographic and pathophysiological covariates on the PK of T-DM1 was explored to better understand the clinical factors that might affect exposure and clinical outcome for individual patients.

Methods: For the current analysis, 9934 T-DM1 serum concentration-time data points from 671 patients were simultaneously fitted using NONMEM® software. T-DM1 concentration-time data to date are best described using a 2-compartment linear model. All relevant and plausible covariates likely to have an effect on T-DM1 systemic exposure, or likely to have clinical relevance, were explored for possible correlation with the key T-DM1 PK parameters of clearance (CL) and central volume of distribution (Vc). These covariates include those related to demographics, renal and hepatic function, disease status, and treatment history.

Results: The estimated CL for T-DM1 is 0.68 L/day, Vc is 3.13 L, and the terminal half-life is 3.94 days. Interindividual variability (IIV) of the base model is 25.6% and 17.5% for CL and Vc, respectively. Patients with greater body weight, sum of longest dimension of target lesions, serum concentration of shed HER2 extracellular domain, and aspartate aminotransferase concentrations, as well as patients with lower serum albumin and baseline trastuzumab concentrations, have statistically faster CL. Patients with greater body weight also have statistically larger Vc. Incorporation of these covariates (P<0.001 by likelihood ratio test) decreased IIV of CL and Vc to 19.1% and 11.7%, respectively. All covariates together explain 44.4% and 55.8% of IIV in CL and Vc, respectively. The model sensitivity analysis suggests that a patient with a statistically significant PK covariate value at the 5th or 95th percentile of the population will have a <20% difference in cumulative exposure (as represented by area under the T-DM1 concentration-time curve) compared with a typical patient with a median covariate value.

Conclusions: A relatively small IIV for the estimated T-DM1 PK parameters of CL and Vc was observed. None of the evaluated covariates had a clinically meaningful magnitude of effect on T-DM1 exposure (<20% difference for patients with 5th and 95th percentiles vs patients with median value of covariates) that would justify a further dose adjustment. The body weight–based dose of 3.6 mg/kg q3w without further correction for other factors is considered appropriate in ongoing clinical trials.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-24.

Cold-nuclear-matter effects on heavy-quark production in d+Au collisions at sqrt[S(NN)]=200 GeV

The PHENIX experiment has measured electrons and positrons at midrapidity from the decays of hadrons containing charm and bottom quarks produced in d+Au and p+p collisions at sqrt[S(NN)]=200 GeV in the transverse-momentum range 0.85 ≤ p(T)(e) ≤ 8.5 GeV/c. In central d+Au collisions, the nuclear modification factor R(dA) at 1.5<p(T)<5 GeV/c displays evidence of enhancement of these electrons, relative to those produced in p+p collisions, and shows that the mass-dependent Cronin enhancement observed at the Relativistic Heavy Ion Collider extends to the heavy D meson family. A comparison with the neutral-pion data suggests that the difference in cold-nuclear-matter effects on light- and heavy-flavor mesons could contribute to the observed differences between the π(0) and heavy-flavor-electron nuclear modification factors R(AA).

Measurement of direct photons in Au+Au collisions at √(s(NN))=200 GeV

We report the measurement of direct photons at midrapidity in Au+Au collisions at √(s(NN))=200 GeV. The direct photon signal was extracted for the transverse momentum range of 4 GeV/c<p(T)<22 GeV/c, using a statistical method to subtract decay photons from the inclusive photon sample. The direct photon nuclear modification factor R(AA) was calculated as a function of p(T) for different Au+Au collision centralities using the measured p+p direct photon spectrum and compared to theoretical predictions. R(AA) was found to be consistent with unity for all centralities over the entire measured p(T) range. Theoretical models that account for modifications of initial direct photon production due to modified parton distribution functions in Au and the different isospin composition of the nuclei predict a modest change of R(AA) from unity. They are consistent with the data. Models with compensating effects of the quark-gluon plasma on high-energy photons, such as suppression of jet-fragmentation photons and induced-photon bremsstrahlung from partons traversing the medium, are also consistent with this measurement.

A novel thin-layer amperometric detector based on chemically modified ring-disc electrode and its application for simultaneous measurements of nitric oxide and nitrite in rat brain combined with in vivo microdialysis

A novel thin-layer amperometric detector (TLAD) based on chemically modified ring-disc electrode and its application for simultaneous measurements of nitric oxide (NO) and nitrite (NO(2)(-)) in rat brain were demonstrated in this work. The ring-disc electrode was simultaneously sensitive to nitric oxide (NO) and nitrite (NO(2)(-)) by modifying its inner disc with electropolymerized film of cobalt(II) tetraaminophthalocyanine (polyCoTAPc)/Nafion and its outer ring with poly(vinylpyridine) (PVP), respectively. The ring-disc electrode was used to constitute a novel TLAD in radial flow cell for simultaneous measurements of NO and NO(2)(-) in rat brain combined with techniques of high performance liquid chromatography (HPLC) and in vivo microdialysis. It was found that the basal concentration of NO in the caudate nucleus of rat brain is lower than 1.0x10(-7) mol l(-1), NO(2)(-) concentration is 5.0x10(-7) mol l(-1) and NO exists in brain maybe mainly in the form of its decomposed product.

Evaluation of the GenoType® MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection

OBJECTIVE

To assess the new GenoType® MTBDRplus assay for the rapid detection of multidrug-resistant tuberculosis (MDR-TB) in comparison with DNA sequencing to identify drug resistance mutation profiles in China.

DESIGN

Using MTBDRplus, drug susceptibility testing (DST) and DNA sequencing, 237 Mycobacterium tuberculosis strains were tested.

RESULTS

The sensitivity of MTBDRplus was 75.0% (126/168) for isoniazid (INH) resistant strains, and 93.5% (157/168) for rifampicin (RMP) resistant strains. It correlated well with sequencing, with 94.9% and 99.6% agreement for each strain category and 100% specificity for all categories. The two most common rpoB mutations were S531L (53.6%, 90/168) and D516G (17.3%, 29/168) in RMP-resistant strains. INH resistance was dominated by the katG 315 locus (S to T, N, R, I) mutation (73.7%, 124/168), and a rare katG mutation, S315N (6.5%, 11/168), not covered by MTBDRplus was identified. The mutation combination inhA-15/inhA-8 and katG315 (34 strains) was characteristically displayed in MDR-TB strains (23.5%), but not in INH-monoresistant strains.

CONCLUSIONS

Although Genotype MTBDRplus is a rapid and reliable molecular test for detecting MDR-TB, a significant proportion of strains in China contain a rare katG S315N mutation that would be missed by the assay. Further improvements may be achieved by incorporating this mutation into the assay to increase sensitivity in detecting INH resistance in China.

Observation of direct-photon collective flow in Au + Au collisions at √s(NN)] = 200 GeV

The second Fourier component v(2) of the azimuthal anisotropy with respect to the reaction plane is measured for direct photons at midrapidity and transverse momentum (p(T)) of 1-12 GeV/c in Au + Au collisions at √s(NN)] = 200 GeV. Previous measurements of this quantity for hadrons with p(T) < 6 GeV/c indicate that the medium behaves like a nearly perfect fluid, while for p(T) > 6 GeV/c a reduced anisotropy is interpreted in terms of a path-length dependence for parton energy loss. In this measurement with the PHENIX detector at the Relativistic Heavy Ion Collider we find that for p(T) > 4 GeV/c the anisotropy for direct photons is consistent with zero, which is as expected if the dominant source of direct photons is initial hard scattering. However, in the p(T) < 4 GeV/c region dominated by thermal photons, we find a substantial direct-photon v(2) comparable to that of hadrons, whereas model calculations for thermal photons in this kinematic region underpredict the observed v(2).

SU-E-J-45: Validation of the ExacTrac Virtual Isocenter Based Target Localization Method

PURPOSE

With no stable landmarks available for localization, a 'virtual isocenter' "'or surrogate landmark near the target'" can be used for image guidance. However, using a virtual isocenter in ExacTrac has not been thoroughly validated. This study evaluates its target localization accuracy and investigates the impact of two different couch correction sequences.

METHODS

A CT scan was acquired on an anthropomorphic thoracic phantom with a 2mm-diameter ball bearing (BB) marker implanted in thelung region. A treatment plan was created with isocenter placed at the BB center, and exported to ExacTrac. In ExacTrac, a virtual isocenter wasplaced on a spine vertebral body where three translational shifts (8.8cm laterally, 1.5cm longitudinally and 6cm vertically) were present. A series ofcouch rotations (+/-3 degrees, 1 degree increment) was intentionally applied to simulate angular setup variations. For each rotation, two stereoscopic x-rayimages were acquired and fused using the ExacTrac 6D registrationalgorithm. Calculated shifts were applied using two sequences: (1)automatic 5D corrections (three translations/two robotic couch rotations) followed by manual couch rotation; (2) manual couch rotation then automatic 5D corrections. After each ExacTrac localization, orthogonal (anterior-posterior and right-lateral) portal images were acquired to quantify BB center deviations from the radiation isocenter as an indicator of residual error.

RESULTS

Minimal difference between investigated table correction sequences was observed. Average translational deviations between the BB and radiation isocenter (mean+/-1SD) were 0.3+/-0.3mm and 1.0+/-0.2mm for lateral and vertical axis respectively. Longitudinally, the deviations were 0.8+/-0.4mm from the anterior-posterior image and 0.1+/-0.3mm from the right-lateral image. The systematic difference (0.7+/-0.1 mm) between thetwo may have been attributed to gantry sagging during rotation.

CONCLUSIONS

ExacTrac system successfully corrected angular shifts using the virtual isocenter method in a rigid phantom setup. The sequence ofcouch correction did not influence the localization accuracy. Further patient study is warranted.

SU-E-J-59: Dual Imaging Guided Localization System for Spine Radiosurgery

PURPOSE

To compare localization accuracies between an ExacTrac and cone beam computed tomography (CBCT) systems for single fraction spine adiosurgery. The work also aimed to evaluate the inherent systematic deviation of both ExacTrac and CBCT systems to achieve highly accurate localization in the spine radiosurgery.

METHODS

ExacTrac and CBCT imaging systems were evaluated using the linac isocenter as the mutual reference point. First, a BB was placed in an anthropomorphic pelvic phantom. The phantom was localized with both imaging systems and the procedure was repeated 12 times. These results were used to devise a localization protocol using both imaging systems in spine radiosurgery, and employed for 51 patients (81 isocenters) prescribed for single fraction treatment. The displacement discrepancy between the isocenter and two systems were quantified in four dimensions (three translations, one rotation). A Student's two-tailed t-test was used to test for significant differences between the two imaging systems.

RESULTS

The phantom study showed 1.4±0.5, 0.6±0.5, and 0.1±0.5 mm differences between the two imaging systems in the anterior/posterior (A/P), superior/inferior (S/I) and left/right (L/R) directions, respectively. The angular difference was minimal along all three axes. The patient study revealed similar isocenter discrepancies between ExacTrac and CBCT of 1.1 ± 0.7 mm, 1.0±0.9 mm, and 0.2±0.9 mm in the A/P, S/I, and L/R directions, respectively, with the A/P and S/I directions showing statistical significance ((t(80) = 13.5 and 7.6 respectively, p = 0.000). The couch yaw discrepancy was 0 ± 0.3°. Overall, 1 mm systematic differences were observed in the A/P and S/I directions between ExacTrac and CBCT localization systems, both in phantom and patient. A procedure was developed to mitigate this systematic discrepancy.

CONCLUSIONS

These findings have justified our patient localization tolerance levels of 2 mm translation and 1 degree rotation for spine SRS treatment.